FDA Won’t Require A Verification Study For Genzyme’s Lumizyme
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme expects to resubmit its BLA, which received a complete response, by mid-May and have a six-month review.
You may also be interested in...
ViroPharma Could Manufacture Cinryze "At Risk" Starting Next Year
Delay in application for industrial scale production illustrates the challenges that biosimilar manufacturers will face.
ViroPharma Could Manufacture Cinryze "At Risk" Starting Next Year
Delay in application for industrial scale production illustrates the challenges that biosimilar manufacturers will face.
FDA Biosimilars Meeting Seeks Input On Product Naming, Foreign Data And Exclusivity
Two-day public hearing in November will cover nearly all aspects of the new pathway except the patent challenge mechanism.